Company Overview and News

 
Glenmark Pharmaceuticals Limited - Press Release

13h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GLENMARK 532296 GLKQY

 
Elite Pharmaceuticals Files ANDA for Codeine and Acetaminophen Combo

2018-09-18 globenewswire
NORTHVALE, N.J., Sept. 18, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced that it has filed an Abbreviated New Drug Application (ANDA) with the US Food and Drug Administration (FDA) for a generic version of Tylenol® with Codeine (acetaminophen and codeine phosphate) 300mg/7.
GLENMARK 532296 ELTP GLKQY

 
Supreme Court lifts ban on sale of Saridon and 2 other drugs

2018-09-17 freepressjournal.in
The Supreme Court on Monday lifted ban on sale of Saridon and two other drugs. Saridon is a medical drug which is used to get relief from headache. Last month, the ministry of health and family welfare (MOHFW) had banned the manufacture, sale or distribution of 328 fixed dose combinations (FDCs) in public interest. It had also restricted the manufacture, sale or distribution of six FDCs, subject to certain conditions.
GLENMARK 532296 ALKEM 539523 GLKQY

 
Glenmark Pharma gets USFDA nod for menopause symptom relief drug

2018-09-17 moneycontrol
Glenmark Pharmaceuticals has received final approval from the US health regulator for generic version of Nordisk Inc's VAGIFEM, used for providing relief from menopause symptom.
GLENMARK 532296 GLKQY

 
Glenmark Pharmaceuticals Limited - Press Release

2018-09-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GLENMARK 532296 GLKQY

 
Glenmark Pharmaceuticals Limited - News Clarification

2018-09-10 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GLENMARK 532296 GLKQY

 
Glenmark Pharmaceuticals Limited - Shareholders meeting

2018-09-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GLENMARK 532296 GLKQY

 
Donate Rs 1.50 crore for Kerala flood relief, Bombay HC directs guilty pharma co

2018-08-31 freepressjournal.in
Mumbai: The Bombay High Court has ordered a pharmaceutical company to deposit Rs 1.50 crore towards the Kerala Chief Minister’s Fund for flood relief work in a trademark infringement case.
GLENMARK 532296 GLKQY

 
Glenmark Pharmaceuticals Limited - Press Release

2018-08-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GLENMARK 532296 GLKQY

 
Glenmark Pharmaceuticals Limited - Shareholders meeting

2018-08-24 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GLENMARK 532296 GLKQY

 
Glenmark Pharmaceuticals Limited - AGM/Book Closure

2018-08-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
GLENMARK 532296 GLKQY

 
Harbour BioMed Inks Partnership Deal with Sichuan Kelun-Biotech Worth $350 Million-Plus

2018-08-20 biospace
Harbour BioMed signed an exclusive strategic partnership deal with Sichuan Kelun-Biotech Biopharmaceutical Co. to develop and commercialize an anti-PD-L1 antibody, A167, currently in Phase II development.
GLENMARK 532296 GLKQY

 
Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study

2018-08-14 globenewswire
NORTHVALE, N.J., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB: ELTP) a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today reported positive topline results from pivotal bioequivalence studies conducted for an undisclosed immediate-release antibiotic generic product being co-developed with SunGen Pharma.
GLENMARK 532296 ELTP GLKQY

 
Glenmark inks pact with private equity firm True North

2018-08-11 moneycontrol
Glenmark Pharmaceuticals said it has entered into a collaboration with private equity firm True North for its orthopaedic and pain management business for India and Nepal market.
GLENMARK 532296 GLKQY

 
Glenmark Pharma Q1 profit at ₹232.99 crore

2018-08-11 livemint
New Delhi: Pharma major Glenmark Pharmaceuticals on Friday reported consolidated net profit of ₹232.99 crore in the first quarter ended 30 June 2018. The company had posted consolidated net profit of ₹333.38 crore in the same quarter last fiscal, Glenmark Pharmaceuticals said in a BSE filing.
GLENMARK 532296 GLKQY

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...